T-cell based cancer immunotherapy: direct or redirected tumor-cell recognition?
In development of strategies for immunotherapy of cancer a new emphasis is emerging, termed T-cell retargeting, which involves artificial redirection of cytotoxic T lymphocytes (CTL) against cancer cells, using bispecific reagents. In this article, Gideon Beun, Cornelis van de Velde and Gert Jan Fleuren evaluate this potential strategy for cellular immunotherapy, and propose how the gap between in vitro results and clinical application might be bridged.
Beun
G D
GD
Dept of Surgery, Academic Hospital Leiden, The Netherlands.
van de Velde
C J
CJ
Fleuren
G J
GJ
D000818:Animals; D003602:Cytotoxicity, Immunologic; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D009369:Neoplasms / Q000276:immunology / Q000628:therapy*; D013601:T-Lymphocytes / Q000276:immunology*